Last reviewed · How we verify

NCT04683172: STIMPAL

Transcranial Direct-current Stimulation (tDCS) Efficacy in Refractory Cancer Pain.

Status unknown NA Last updated 14 September 2023
What this trial tests

NA trial testing Active Transcranial Direct Current Stimulation in Cancer Pain in 70 participants. Status unknown.

Timeline
15 May 2021
Primary endpoint
15 June 2024
15 June 2024

Quick facts

Lead sponsorElsan
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposesupportive care
Enrollment70
Start date15 May 2021
Primary completion15 June 2024
Estimated completion15 June 2024
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Elsan — full company profile →

Who can join

18 and older, any sex, with Cancer Pain or Refractory Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pain is a common symptom in palliative care cancer patients and is often insufficiently relieved. The 2010 INCA report showed that France is not an exception to this worldwide observation (synopsis of the 2010 national survey). This report shows that pain is the symptom that these patients fear the most and that it dramatically impacts their quality of life. These patients may experience nociceptive pain related to stimulation of sensory nerve endings by the tumour. When tumour resection is impossible, a symptomatic analgesic treatment is generally proposed, mainly consisting of administration of opioid analgesics. At high doses, this treatment induces adverse effects, especially drowsiness and psychomotor retardation that impair the patient's quality of life. They may also experience neuropathic pain, secondary to anatomical lesions or functional impairment of nerve structures (peripheral nerves or cerebral or spinal tracts) related to repeated surgical procedures and/or radiotherapy. This type of pain may respond to antiepileptic or antidepressant drugs. At high doses, these treatments also induce adverse effects fairly similar to those observed during treatment of nociceptive pain. As these two types of treatment often need to be coprescribed, these patients frequently present an almost permanent state of drowsiness at the end of life, preventing all normal activities of daily living. In recent years, noninvasive brain stimulation (NIBS) techniques (transcranial magnetic stimulation (rTMS) or transcranial direct-current stimulation (tDCS)) have been successfully used to treat chronic pain. It was shown that these NIBS techniques can improve pain in cancer patients in the palliative care setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Active Transcranial Direct Current Stimulation

Trials testing the same drug.

Other recruiting trials for Cancer Pain

Currently open trials in the same condition.

Other Elsan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04683172.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing